Furthermore, another CB1 antagonist, rimonabant, attenuated hepatic steatosis through repression of hepatomegaly, reduced hepatic TNF‐α levels, and increased plasma adiponectin levels in an obese Zucker fa/fa rat model.17 This evidence concerns the gene CNR1 and fatty liver disease.